PRISM Registry: Pseudobulbar Affect Registry Series

clinical trial

Details

Instance of: clinical trial
Start time: May 2011
End time: September 2012
Country: United States
Main subject: sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, motor neuron disease, multiple sclerosis
minimum age: 18
number of participants: 5290
research site: Avanir Pharmaceuticals (United States)
sponsor: Avanir Pharmaceuticals (United States)
study type: observational study
title: PRISM Registry: Pseudobulbar Affect Registry Series

Nothing in the MetaHistoryBook collection references this item yet.